Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2024

This “Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Platelet-derived growth factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Platelet-derived growth factor receptor antagonists Understanding

Platelet-derived growth factor receptor antagonists: Overview

Platelet-derived growth factor receptors belong to class III receptor tyrosine kinases. In human, there are four genes expressing PDGF chains: PDGF-A, B, C and D. PDGFA, PDGFB, PDGFC, and PDGFD genes are located on chromosomes 7, 22, 4, and 11, respectively. Platelet-derived growth factor plays a significant role in cell proliferation and embryonic development and is regulated through the platelet-derived growth factor receptor (PDGFR). Platelet-derived growth factor receptor (PDGFR) is a compelling target for developing therapeutic agents to treat diseases associated with overactivated platelet-derived growth factor (PDGF) signaling and has proved to be particularly encouraging for cancer treatment.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Platelet-derived growth factor receptor antagonists R&D. The therapies under development are focused on novel approaches for Platelet-derived growth factor receptor antagonists.

Platelet-derived growth factor receptor antagonists Emerging Drugs Chapters

This segment of the Platelet-derived growth factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Platelet-derived growth factor receptor antagonists Emerging Drugs

Lenvatinib: Eisai Lenvatinib (LENVIMA) is orally available multi-kinase inhibitor and antineoplastic agent that is used in treatment of advanced, metastatic medullary thyroid cancer and refractory renal cell carcinoma. LENVIMA is also used as the first treatment for hepatocellular carcinoma. The drug is in clinical development for other cancers and solidtumors.

Quizartinib: Daiichi Sankyo Company Quizartinib is an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Quizartinib is use for acute myeloid leukemia treatment and is in clinical development for Myelodysplastic syndromes and Precursor cell lymphoblasticleukaemia-lymphoma.

Platelet-derived growth factor receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Platelet-derived growth factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Platelet-derived growth factor receptor antagonists

There are approx. 8+ key companies which are developing the Platelet-derived growth factor receptor antagonists. The companies which have their Platelet-derived growth factor receptor antagonists drug candidates in the most advanced stage, i.e. Phase III include, Eisai.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Platelet-derived growth factor receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Platelet-derived growth factor receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Platelet-derived growth factor receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Platelet-derived growth factor receptor antagonists drugs.

Platelet-derived growth factor receptor antagonists Report Insights

• Platelet-derived growth factor receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Platelet-derived growth factor receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Platelet-derived growth factor receptor antagonists drugs?
• How many Platelet-derived growth factor receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Platelet-derived growth factor receptor antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Platelet-derived growth factor receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Platelet-derived growth factor receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eisai
• Daiichi Sankyo Company
• Jiangsu Hengrui Medicine
• Boehringer Ingelheim
• Betta Pharmaceuticals
• Tyrogenex
• Pfizer
• Metagone Biotech
• Bayer Healthcare
• AROG Pharmaceuticals
• Pfizer
• Molecular Partners
• Xspray Pharma

Key Products

• Lenvatinib
• Quizartinib
• Famitinib
• Nintedanib
• Vorolanib
• Axitinib
• MGD 1509
• Regorafenib
• Crenolanib
• AGN-151200
• Sorafenib nanoparticle formulation

This product will be delivered within 2 business days.